Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.37 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.37 |
| ▸ | FABP7 | O15540 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678390 | 1.00 | IDO1 (0.39) | IDO1AGXTLTA4HTUBB4ATUBB | |
| SCHEMBL14074089 | 0.87 | PDPK1 (0.37) | ALDH1A1P2RX4HTR6 | |
| SCHEMBL4859043 | 0.87 | PDPK1 (0.37) | ALDH1A1P2RX4HTR6 | |
| SCHEMBL14074344 | 0.84 | CYP3A4 (0.39) | LTA4HALDH1A1 | |
| SCHEMBL4862964 | 0.84 | CYP3A4 (0.39) | LTA4HALDH1A1 | |
| SCHEMBL14074047 | 0.79 | LMNA (0.40) | TP53HTR6 | |
| SCHEMBL4852823 | 0.79 | LMNA (0.40) | TP53HTR6 | |
| SCHEMBL4854361 | 0.78 | KDM1A (0.44) | ALDH1A1HTT | |
| SCHEMBL14010983 | 0.78 | KDM1A (0.44) | ALDH1A1HTT | |
| SCHEMBL4854356 | 0.78 | KDM1A (0.44) | ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7420003-B2 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | ASTRAZENECA AB (SE) | 2008-09-02 | — | — | US | claimed |
| US-20050014721-A1 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | FAGNOU KEITH (CA) | 2005-01-20 | — | — | US | claimed |
| EP-1498406-A1 | Novel hydronaphthalene compounds, prepared by a rhodium catalysed ring opening reaction in the presence of phosphine ligand | AstraZeneca AB (SE) | 2005-01-19 | — | — | EP | claimed |
| EP-1228024-B1 | NOVEL HYDRONAPHTHALENE COMPOUNDS, PREPARED BY A RHODIUM CATALYZED RING OPENING REACTION IN THE PRESENCE OF PHOSPHINE LIGAND | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | claimed |
| US-20030144275-A1 | Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | claimed |
| US-20080300271-A1 | Novel compounds and a novel process for their preparation | FAGNOU KEITH | 2008-12-04 | — | — | US | disclosed |
| US-20080300271-A1 | Novel compounds and a novel process for their preparation | FAGNOU KEITH | 2008-12-04 | — | — | US | disclosed |
| US-20080300271-A1 | Novel compounds and a novel process for their preparation | FAGNOU KEITH | 2008-12-04 | — | — | US | disclosed |
| US-7420003-B2 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | ASTRAZENECA AB (SE) | 2008-09-02 | — | — | US | disclosed |
| US-7420003-B2 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | ASTRAZENECA AB (SE) | 2008-09-02 | — | — | US | disclosed |
| US-20050014721-A1 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | FAGNOU KEITH (CA) | 2005-01-20 | — | — | US | disclosed |
| EP-1498406-A1 | Novel hydronaphthalene compounds, prepared by a rhodium catalysed ring opening reaction in the presence of phosphine ligand | AstraZeneca AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| EP-1228024-B1 | NOVEL HYDRONAPHTHALENE COMPOUNDS, PREPARED BY A RHODIUM CATALYZED RING OPENING REACTION IN THE PRESENCE OF PHOSPHINE LIGAND | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-6784210-B2 | DECYCLIZATION OF OXABENZONORBORNADIENES OR AZABICYCLIC COMPOUNDS IN THE PRESENCE OF CATALYSTS TO FORM NAPHTHALENES, SUCH AS 2-METHOXY-1,2-DIHYDRONAPHTHALEN-1-OL, USED AS ANALGESICS, ANTICARCINOGENS OR VIRICIDES; CATALYSIS | ASTRAZENECA AB (SE) | 2004-08-31 | — | — | US | disclosed |
| US-20030144275-A1 | Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis | ASTRAZENECA AB (SE) | 2003-07-31 | — | — | US | disclosed |
| US-6525068-B1 | Such as 2-pyrrolidin-1-yl-1,2-dihydro-naphthalen-1-ol; reac-tion of oxabenzonorbornadienes with nucleophiles; pain, parkinson's disease, cancer, aids | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300271-A1 | Novel compounds and a novel process for their preparation | NUDT1, NCL, NUCB2 | IDO1 3275/4885AGXT 4263/4885LTA4H 1178/4885 |
| US-20050014721-A1 | reacting oxabenzonorbornadiene with nucleophiles;in presence of rhodium complex catalyst forming 2-pyrrolidin-1-ol-1,2-dihydronaphthalen-1-ol; drug used as analgesics, Parkinson's disease, anticancer agents; aids | PARK7, OPRD1, OPRK1 | IDO1 212/4885AGXT 4680/4885LTA4H 2634/4885 |
| US-20030144275-A1 | Decyclization of oxabenzonorbornadienes or azabicyclic compounds in the presence of catalysts to form naphthalenes, such as 2-methoxy-1,2-dihydronaphthalen-1-ol, used as analgesics, anticarcinogens or viricides; catalysis | DDT, HPD, DHODH | IDO1 293/4885AGXT 4447/4885LTA4H 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.